| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4022954 | Journal Français d'Ophtalmologie | 2016 | 6 Pages |
Abstract
These results showed that ranibizumab was able to maintain stable VA in clinical practice for at least 2Â years in patients with CNV secondary to PXE, and to significantly reduce the frequency of neovascularization relapses, with a limited number of injections. The treatment was well tolerated by the patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
J.-M. Ebran, G. Mimoun, S.-Y. Cohen, T. Grenet, A. Donati, M.-J. Jean-Pastor, A. Ponthieux, C. Bouchet,